Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Final outcomes of the phase II OGSG1902 trial

Takeshi Omori, Shunji Endo, Ryo Tanaka, Toshifumi Yamaguchi, Hiromichi Miyagaki, Junji Kawada, Naoki Takahashi, Toru Masuzawa, Haruna Furukawa, Yuya Sato, Atsushi Takeno, Naoki Shinno, Ryohei Kawabata, Shinsuke Katsuyama, Shigeyoshi Higashi, Yukinori Kurokawa, Toshimasa Tsujinaka, Toshio Shimokawa, Taroh Satoh

ASCO-GI 2026, San Francisco, California, United States 8-10 Jan2026